Literature DB >> 32933945

Convalescent plasma for covid-19.

Lise J Estcourt1, David J Roberts1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32933945     DOI： 10.1136/bmj.m3516

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.

Authors:  Sixten Körper; Manfred Weiss; Daniel Zickler; Thomas Wiesmann; Kai Zacharowski; Victor M Corman; Beate Grüner; Lucas Ernst; Peter Spieth; Philipp M Lepper; Martin Bentz; Sebastian Zinn; Gregor Paul; Johannes Kalbhenn; Matthias M Dollinger; Peter Rosenberger; Thomas Kirschning; Thomas Thiele; Thomas Appl; Benjamin Mayer; Michael Schmidt; Christian Drosten; Hinnerk Wulf; Jan Matthias Kruse; Bettina Jungwirth; Erhard Seifried; Hubert Schrezenmeier
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

2.  Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray.

Authors:  Annekathrin Haberland; Johannes Müller
Journal:  Chem Biol Drug Des       Date:  2021-10-31       Impact factor: 2.873

3.  Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.

Authors:  Henry T Peng; Shawn G Rhind; Andrew Beckett
Journal:  JMIR Public Health Surveill       Date:  2021-04-07

Review 4.  Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.

Authors:  Nandeeta Samad; Temitayo Eniola Sodunke; Hasan Al Banna; Ashmita Sapkota; Aneeka Nawar Fatema; Katia Iskandar; Dilshad Jahan; Timothy Craig Hardcastle; Tanzina Nusrat; Tajkera Sultana Chowdhury; Mainul Haque
Journal:  Risk Manag Healthc Policy       Date:  2020-11-23

5.  SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.

Authors:  Chandima Jeewandara; Deshni Jayathilaka; Laksiri Gomes; Ananda Wijewickrama; Eranga Narangoda; Damayanthi Idampitiya; Dinuka Guruge; Ruwan Wijayamuni; Suranga Manilgama; Graham S Ogg; Chee Wah Tan; Lin-Fa Wang; Gathsaurie Neelika Malavige
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

6.  Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.

Authors:  Fernando Anselmo de Oliveira; Mariana Penteado Nucci; Gabriel Nery de Albuquerque Rego; Arielly da Hora Alves; Luciana Cavalheiro Marti; Leopoldo Penteado Nucci; Javier Bustamante Mamani; Lionel Fernel Gamarra
Journal:  Einstein (Sao Paulo)       Date:  2021-04-19

7.  Convalescent plasma for SARS-CoV-2 infection: win or learn.

Authors:  Enric Contreras-Barbeta; Anna Millan; Jordi Rello
Journal:  Eur Respir J       Date:  2022-02-10       Impact factor: 16.671

Review 8.  Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy.

Authors:  Hebat-Allah Hassan Nashaat; Maha Anani; Fadia M Attia
Journal:  Blood Res       Date:  2022-03-31

Review 9.  How should we use convalescent plasma therapies for the management of COVID-19?

Authors:  Erica M Wood; Lise J Estcourt; Zoe K McQuilten
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

Review 10.  Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.

Authors:  Tejpal Gupta; Sadhana Kannan; Babusha Kalra; Prafulla Thakkar
Journal:  Transfus Med       Date:  2021-06-29       Impact factor: 2.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.